Skip to main content
SpringerLink
Log in

Intravesical epirubicin in the prophylaxis of superficial bladder cancer

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Forty-five patients who underwent transurethral resection (TUR) for Ta-Tl superficial bladder cancer were included in the study. Fourteen patients who had TUR alone were assigned to the control group. Epirubicin therapy was started two weeks after complete TUR of the tumour. Epirubicin in a dose of 50 mg diluted in 50 ml saline was instilled weekly for 8 weeks in the epirubicin group. The mean follow-up was 24 months.

Although recurrence rate was higher in the control group (64.2% versus 32.2%), it was not found to be statistically significant (p=0.0914, chi-square test). Tumour-free intervals in patients with recurrent disease were significantly longer in the epirubicin group (p<0.05, Mann-Whitney U-test).

In conclusion: intravesical epirubicin therapy, which both reduces recurrence rate and prolongs time to recurrence, was found to be effective in the prophylaxis of superficial bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg, E., Boring, C. C., Squires, T. S.: Cancer statistics, 1990.CA, 40, 9 (1990).

    PubMed  CAS  Google Scholar 

  2. Fitzpatrick, J. D., Reda, M.: Bladder carcinoma in patients 40 years old or less.J. Urol., 135, 53 (1986).

    PubMed  CAS  Google Scholar 

  3. Fitzpatrick, J. M., West, A. B., Buttler, M. R., Lane, V., O'Flynn, J. D.: Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection.J. Urol., 135, 920 (1986).

    PubMed  CAS  Google Scholar 

  4. Van Der Meijden, A. P. M., Kurth, K., Oosterlinck, W., Debruyne, F. M. J. and Members of the EORTC Genito-Urinary Group: Intravesical therapy with Adriamycin and 4-epirubicin for superficial bladder sancer. The experience of the EORTC Group.Cancer Chemother. Pharmacol., 30 (Suppl.), 595 (1982).

    Google Scholar 

  5. Herr, H. W., Laudone, V. P., Whitmore, W. F. Jr.: An overview of intravesical therapy for superficial bladder tumors.J. Urol., 138, 1363 (1987).

    PubMed  CAS  Google Scholar 

  6. Chai, M., Wientjes, M. G., Badalement, R. A., Burgers, J. K., Au, J. L. S.: Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients.J. Urol., 152, 374 (1994).

    PubMed  CAS  Google Scholar 

  7. Lutzeyer, W., Rubben, H., Dahm, H.: Prognostic parameters in superficial bladder cancer: An analysis of 315 cases.J. Urol., 127, 250 (1982).

    PubMed  CAS  Google Scholar 

  8. Lundbeck, F., Pedersen, D., Stroyer, I., Uldall, A.: Absorption of doxorubicin hydrochloride during bladder washings in treatment of noninvasive bladder tumors.Urology, 18, 161 (1981).

    Article  PubMed  CAS  Google Scholar 

  9. Larson, A., Eksborg, S., Fritjoffson, A.: Intravesical instillation of adriamycin early after transurethral resection measurements of plasma levels.Eur. Urol., 10, 398 (1984).

    PubMed  CAS  Google Scholar 

  10. Brantley, T., David, C.: Complications of intravesical chemotherapy.Urol. Clin. North. Am., 19, 529 (1992).

    Google Scholar 

  11. Melekos, M. D., Dauahauer, H., Fokaefs, E., Barbalias, G.: Intravesical instillations of 4-Epidoxorubicin (Epirubicin) in the prophylactic treatment of superficial bladder cancer: Results of a controlled prospective study.J. Urol., 147, 371 (1992).

    PubMed  CAS  Google Scholar 

  12. Fernando, C. S., Fernando, F., Teixeira, B., Almedia, S.: 4-Epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.Eur. Urol., 21, 42 (1992).

    Google Scholar 

  13. Burk, K., Kurt, K. H., Newling, D.: Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.Prog. Clin. Biol. Res., 303, 423 (1989).

    PubMed  CAS  Google Scholar 

  14. Whelan, P., Cumming, J. A., Garvie, W. H. H., Hargreave, T. B., Kirk, D., Newling, D. W. W., Robinson, M. R. G., Smith, P. H.: Multi-centre Phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer.Br. J. Urol., 67, 600 (1991).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Haydarpaşa Numune Hospital, Istanbul, Turkey

    F. Şengör, M. Beysel, K. Erdoĝan, A. Erol & D. Tuzluoĝlu

Authors
  1. F. Şengör
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Beysel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Erdoĝan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Erol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Tuzluoĝlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Şengör, F., Beysel, M., Erdoĝan, K. et al. Intravesical epirubicin in the prophylaxis of superficial bladder cancer. International Urology and Nephrology 28, 201–206 (1996). https://doi.org/10.1007/BF02550861

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02550861

Keywords

Search

Navigation